Recapping just some of the notable data coming out of ESMO 2024:
-Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC)
-AMBASSADOR (adjuvant pembrolizumab in bladder cancer)
-NIAGRA (perioperative durvalumab in bladder cancer)
-ADRIATIC (discussed on ASCO recap Pod, but publication now available)
-LEANOX (impact of lean body mass adjustment on oxaliplatin dose)